403 related articles for article (PubMed ID: 9049482)
1. Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM.
Rachman J; Barrow BA; Levy JC; Turner RC
Diabetologia; 1997 Feb; 40(2):205-11. PubMed ID: 9049482
[TBL] [Abstract][Full Text] [Related]
2. Subcutaneous glucagon-like peptide-1 improves postprandial glycaemic control over a 3-week period in patients with early type 2 diabetes.
Todd JF; Edwards CM; Ghatei MA; Mather HM; Bloom SR
Clin Sci (Lond); 1998 Sep; 95(3):325-9. PubMed ID: 9730852
[TBL] [Abstract][Full Text] [Related]
3. Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1 (7-36) amide in patients with NIDDM.
Rachman J; Gribble FM; Barrow BA; Levy JC; Buchanan KD; Turner RC
Diabetes; 1996 Nov; 45(11):1524-30. PubMed ID: 8866556
[TBL] [Abstract][Full Text] [Related]
4. Addition of metformin to exogenous glucagon-like peptide-1 results in increased serum glucagon-like peptide-1 concentrations and greater glucose lowering in type 2 diabetes mellitus.
Cuthbertson J; Patterson S; O'Harte FP; Bell PM
Metabolism; 2011 Jan; 60(1):52-6. PubMed ID: 20152998
[TBL] [Abstract][Full Text] [Related]
5. Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients.
Vilsbøll T; Krarup T; Madsbad S; Holst JJ
Diabetologia; 2002 Aug; 45(8):1111-9. PubMed ID: 12189441
[TBL] [Abstract][Full Text] [Related]
6. Glycaemic effects of incretins in Type 1 diabetes mellitus: a concise review, with emphasis on studies in humans.
Dupre J
Regul Pept; 2005 Jun; 128(2):149-57. PubMed ID: 15780434
[TBL] [Abstract][Full Text] [Related]
7. alpha-Glucosidase inhibition (acarbose) fails to enhance secretion of glucagon-like peptide 1 (7-36 amide) and to delay gastric emptying in Type 2 diabetic patients.
Hücking K; Kostic Z; Pox C; Ritzel R; Holst JJ; Schmiegel W; Nauck MA
Diabet Med; 2005 Apr; 22(4):470-6. PubMed ID: 15787675
[TBL] [Abstract][Full Text] [Related]
8. Overnight GLP-1 normalizes fasting but not daytime plasma glucose levels in NIDDM patients.
Willms B; Idowu K; Holst JJ; Creutzfeldt W; Nauck MA
Exp Clin Endocrinol Diabetes; 1998; 106(2):103-7. PubMed ID: 9628239
[TBL] [Abstract][Full Text] [Related]
9. Glucagon-like peptide 1 (GLP-1) in the treatment of diabetes.
Nauck MA
Horm Metab Res; 2004; 36(11-12):852-8. PubMed ID: 15655719
[TBL] [Abstract][Full Text] [Related]
10. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients.
Toft-Nielsen MB; Madsbad S; Holst JJ
Diabetes Care; 1999 Jul; 22(7):1137-43. PubMed ID: 10388979
[TBL] [Abstract][Full Text] [Related]
11. Blood glucose control in healthy subject and patients receiving intravenous glucose infusion or total parenteral nutrition using glucagon-like peptide 1.
Nauck MA; Walberg J; Vethacke A; El-Ouaghlidi A; Senkal M; Holst JJ; Gallwitz B; Schmidt WE; Schmiegel W
Regul Pept; 2004 Apr; 118(1-2):89-97. PubMed ID: 14759561
[TBL] [Abstract][Full Text] [Related]
12. Glucagon-like peptide I enhances the insulinotropic effect of glibenclamide in NIDDM patients and in the perfused rat pancreas.
Gutniak MK; Juntti-Berggren L; Hellström PM; Guenifi A; Holst JJ; Efendic S
Diabetes Care; 1996 Aug; 19(8):857-63. PubMed ID: 8842604
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic potential of glucagon-like peptide 1 in type 2 diabetes.
Nauck M
Diabet Med; 1996 Sep; 13(9 Suppl 5):S39-43. PubMed ID: 8894470
[TBL] [Abstract][Full Text] [Related]
14. Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes.
Meier JJ; Gallwitz B; Salmen S; Goetze O; Holst JJ; Schmidt WE; Nauck MA
J Clin Endocrinol Metab; 2003 Jun; 88(6):2719-25. PubMed ID: 12788879
[TBL] [Abstract][Full Text] [Related]
15. Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment.
Larsen J; Hylleberg B; Ng K; Damsbo P
Diabetes Care; 2001 Aug; 24(8):1416-21. PubMed ID: 11473079
[TBL] [Abstract][Full Text] [Related]
16. Glucagon-like peptide 1 and its derivatives in the treatment of diabetes.
Nauck MA; Meier JJ
Regul Pept; 2005 Jun; 128(2):135-48. PubMed ID: 15780433
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of beta-cell secretory capacity using glucagon-like peptide 1.
Vilsbøll T; Toft-Nielsen MB; Krarup T; Madsbad S; Dinesen B; Holst JJ
Diabetes Care; 2000 Jun; 23(6):807-12. PubMed ID: 10841001
[TBL] [Abstract][Full Text] [Related]
18. Lack of effect of exendin-4 and glucagon-like peptide-1-(7,36)-amide on insulin action in non-diabetic humans.
Vella A; Shah P; Reed AS; Adkins AS; Basu R; Rizza RA
Diabetologia; 2002 Oct; 45(10):1410-5. PubMed ID: 12378382
[TBL] [Abstract][Full Text] [Related]
19. The entero-insular axis in type 2 diabetes--incretins as therapeutic agents.
Creutzfeldt W
Exp Clin Endocrinol Diabetes; 2001; 109 Suppl 2():S288-303. PubMed ID: 11460578
[TBL] [Abstract][Full Text] [Related]
20. Beta cell response to oral glimepiride administration during and following a hyperglycaemic clamp in NIDDM patients.
van der Wal PS; Draeger KE; van Iperen AM; Martini C; Aarsen M; Heine RJ
Diabet Med; 1997 Jul; 14(7):556-63. PubMed ID: 9223393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
